BioRadar Blog
Biotech trading insights, PDUFA analysis, and market intelligence.
What the Public Data Can and Cannot Tell Us About SELLAS’s Galinpepimut-S in AML
A statistical analysis of SELLAS's Phase 3 REGAL trial of galinpepimut-S (GPS) in AML — what the blinded, pooled event data can and cannot tell us.
Read article →Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Jul 5–Jul 12, 2026)
Here’s what’s on the biotech calendar for July 5–July 12: 2 FDA decision dates, 0 trial catalysts, and 0 earnings reports from tracked companies. 💊 FDA Decisions (PDUFA Dates) Date…
Read article →Best Biotech Catalyst & FDA Calendar Tools (2026)
A fair comparison of the main biotech catalyst and FDA calendar tools in 2026 — BioPharmCatalyst, BiopharmaWatch, BPIQ, FDA Tracker and BioRadar — and how to choose.
Read article →Why SELLAS Might Fail: The Hidden Risks Behind GPS, REGAL, and the AML CR2 Bull Case
Ticker: SLSCompany: SELLAS Life Sciences GroupLead asset: Galinpepimut-S, also known as GPSKey catalyst: Phase 3 REGAL trial in acute myeloid leukemia patients in second remissionCore question: Is the delayed REGAL readout evidence that GPS is…
Read article →Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Jun 28–Jul 5, 2026)
Here’s what’s on the biotech calendar for June 28–July 5: 2 FDA decision dates, 15 trial catalysts, and 0 earnings reports from tracked companies. 💊 FDA Decisions (PDUFA Dates) Date…
Read article →Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Jun 21–Jun 28, 2026)
Here’s what’s on the biotech calendar for June 21–June 28: 0 FDA decision dates, 0 trial catalysts, and 0 earnings reports from tracked companies. 📡 Run-up Radar Highlights Stocks entering…
Read article →Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Jun 14–Jun 21, 2026)
OSTX dominates this week’s catalyst calendar with three trial readouts spanning solid tumors and hematologic malignancies, including a promising CAR-T study in relapsed AML. The week offers a lighter schedule…
Read article →Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Jun 10–Jun 17, 2026)
This week brings a focused slate of clinical readouts, with Osteoxenon (OSTX) commanding attention through two distinct oncology programs. The most intriguing catalyst may be OSTX’s CD33 CAR-T data in…
Read article →Biotech’s Biggest Statistical Fallacy: Why Comparing to Historical Data is an Investor’s Worst Trap
Historical survival data can be useful context — but it becomes dangerous when investors treat it as the control arm their trial will actually face. Biotech investing is notoriously binary—a…
Read article →Biotech Conference Season 2026: Which Events Move Stocks the Most
Biotech conferences are where companies present clinical data for the first time, announce partnerships, and reveal pipeline updates. For traders, conference season creates some of the most predictable volatility windows…
Read article →